Carmustine with or without ethanol for lymphoma transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a chemotherapy drug called carmustine, with or without ethanol (alcohol), to see if it works better for people with lymphoma who are getting a stem cell transplant. You may be eligible if you have Hodgkin or Non-Hodgkin lymphoma, have responded well to treatment, and are healthy enough for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and your doctor thinks you will live at least 6 more months.
- You are well enough to do most daily activities (Karnofsky score of 70% or higher).
- You have Hodgkin lymphoma or Non-Hodgkin lymphoma, and your doctor says you are a candidate for a stem cell transplant.
- Your lymphoma has either completely or partially responded to your last treatment, and you have enough stem cells collected for transplant.
- You have recovered from side effects of earlier chemotherapy, and your heart, lungs, and other organs are working well enough.
- You have not had a stem cell transplant before, and you don't have other active cancers or serious infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a modified chemotherapy “conditioning” plan before an autologous stem cell transplant for people with non-Hodgkin lymphoma. It aims to improve how patients tolerate and recover from the transplant process.
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
This trial tests a new type of cell therapy for people with certain types of lymphoma (Hodgkin or diffuse large B-cell) that did not respond fully to first treatment or came back within a year. The therapy uses modified natural killer (NK) cells that target a protein called CD70 found on the cancer cells.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.